Table 30Sensitivity Analysis Using the Lowest Estimates of Test Sensitivity and Highest Estimates of Specificity*

StrategyColposcopiesIncremental ColposcopiesLife-YearsIncremental Life-YearsICLY
No intervention069016.30
Cytology, q3, age 21;
Cytology and HPV, q5, age 30
13213269123.68107.381
Cytology, q3, age 21;
Cytology and HPV, q3, age 30
1875569153.3829.702
Cytology, q2, age 21;
Cytology and HPV, q3, age 30
2506369172.5019.123
Cytology, q1, age 21;
Cytology and HPV, q3, age 30
3277769191.3218.824
Cytology, q1, age 214047769199.498.179
*

Results are presented as expected colposcopies per 1,000 women, incremental colposcopies, life-years, incremental life-years, and incremental colposcopies per life-year (ICLY) for strategies identified as efficient. Women are assumed to begin screening at age 21 years. For the combined cytology and HPV strategies, cytology-based screening is assumed before age 30 years, with a repeat cytology test for ASC-US results. The strategy of cytology and HPV testing is assumed to begin at age 30 years.

Sensitivity for CIN2+ is 0.200 instead of 0.569; specificity for CIN2+ is 0.990 instead of 0.945; sensitivity for ASC-US is 0.450 instead of 0.762; specificity for ASC-US is 0.756 instead of 0.638.

HC2 sensitivity for CIN2+ is 0.341 instead of 0.860; HC2 specificity for CIN2+ is 0.966 instead of 0.844; HC2 sensitivity for ASC-US is 0.670 instead of 0.892; HC2 specificity for ASC-US is 0.672 instead of 0.641.

From: Addendum

Cover of Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 86s.
Kulasingam SL, Havrilesky L, Ghebre R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.